A small molecule pyroptosis inducer and its application as a tumor sonodynamic therapeutic agent
By designing the small molecule pyroptosis inducer Rd-TTPA, and utilizing the enhanced DA structure and low-frequency ultrasound-mediated reactive oxygen species generation, the problem of targeted tumor cell and deep tumor treatment has been solved, achieving efficient and safe tumor ablation and imaging monitoring.
Patent Information
- Application Number
- CN202311618429.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-28
- Publication Date
- 2026-04-21
- Estimated Expiration
- 2043-11-28
AI Technical Summary
Existing pyroptosis inducers lack the ability to target tumor cells, making it impossible to monitor their retention at the tumor site and their distribution in the body. Furthermore, chemotherapy drugs have tumor resistance and serious toxic side effects, while photodynamic therapy has low killing efficiency for deep tumors and adverse side effects on normal tissues.
A small molecule pyroptosis inducer, Rd-TTPA, was developed. Through an enhanced DA structure composed of N,N-diethylimine, rhodamine scaffold, thiophene, and triphenylamine groups, it utilizes low-frequency ultrasound-mediated reactive oxygen species generation to achieve mitochondrial targeting of tumor cells and near-infrared II fluorescence imaging, thereby enhancing sonodynamic therapy.
Rd-TTPA can efficiently target tumor cell mitochondria, reduce toxic side effects on normal tissues, achieve deep tissue ablation, and has good biocompatibility and imaging monitoring capabilities, thus improving the efficiency and safety of tumor treatment.